Trial Profile

PPAR alpha [peroxisome proliferator-activated receptor-alpha]: A phase 2 dose-finding and safety study for atherogenic dyslipidemia by Eli Lilly

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY 518674 (Primary) ; Fenofibrate
Indications Hypercholesterolaemia; Lipid metabolism disorders
Focus Biomarker; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

25 Mar 2007 Results have been published
06 Dec 2006 Status change
05 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com